Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 10/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25976758 | 0.93 | IL2 (0.54) | IL2ABL1MAPT | |
| SCHEMBL12155920 | 0.83 | IL2 (0.48) | IL2ALDH1A1CYP2C9CYP2C19ABL1 | |
| SCHEMBL25320792 | 0.80 | IL2 (0.45) | IL2ABL1 | |
| SCHEMBL12155820 | 0.78 | IL2 (0.43) | IL2ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12155849 | 0.77 | IL2 (0.58) | IL2ABL1MAPTGAA | |
| SCHEMBL12155827 | 0.77 | STIM1 (0.57) | IL2ALDH1A1CYP2C9CYP2C19ABL1 | |
| SCHEMBL12155559 | 0.76 | STIM1 (0.58) | IL2ALDH1A1CYP2C9CYP2C19ABL1 | |
| SCHEMBL12155794 | 0.76 | STIM1 (0.58) | IL2ALDH1A1CYP2C9CYP2C19ABL1 | |
| SCHEMBL12156152 | 0.75 | IL2 (0.48) | IL2ALDH1A1CYP2C9CYP2C19ABL1 | |
| SCHEMBL1701936 | 0.75 | IL2 (0.58) | IL2ALDH1A1ABL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | claimed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | claimed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | claimed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | claimed |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-07-20 | — | — | US | claimed |
| EP-3261641-B1 | PANCREATITIS TREATMENT | CALCIMEDICA INC (US) | 2023-07-12 | — | — | EP | claimed |
| CN-116261468-A | Methods and compositions for treating acute kidney injury | 钙医学公司 | 2023-06-13 | — | — | CN | claimed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | claimed |
| EP-4153179-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | Calcimedica, Inc. (US) | 2023-03-29 | — | — | EP | claimed |
| CN-115835878-A | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | 钙医学公司 | 2023-03-21 | — | — | CN | claimed |
| US-11311535-B2 | Pancreatitis treatment | CALCIMEDICA, INC. (US) | 2022-04-26 | — | — | US | claimed |
| WO-2021236820-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | CALCIMEDICA, INC. (US) | 2021-11-25 | — | — | WO | claimed |
| US-20180235958-A1 | PANCREATITIS TREATMENT | AVENUE CAPITAL MANAGEMENT II, L.P. | 2018-08-23 | — | — | US | claimed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20180235958-A1 | PANCREATITIS TREATMENT | AVENUE CAPITAL MANAGEMENT II, L.P. | 2018-08-23 | — | — | US | disclosed |
| EP-3261641-A1 | PANCREATITIS TREATMENT | Calcimedica, Inc. (US) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016138472-A1 | PANCREATITIS TREATMENT | CALCIMEDICA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | IL2 84/4885ALDH1A1 4721/4885CYP2C9 4509/4885 |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | IL2 264/4885ALDH1A1 3919/4885CYP2C9 4873/4885 |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | MAVS, ATF1, IL1B | IL2 247/4885ALDH1A1 3903/4885CYP2C9 4880/4885 |
| US-20230226058-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE KIDNEY INJURY | CAMKK2, CAMKK1, ATF1 | IL2 1657/4885ALDH1A1 2998/4885CYP2C9 4820/4885 |
| US-11311535-B2 | Pancreatitis treatment | IAPP, PNLIP, VIP | IL2 105/4885ALDH1A1 4027/4885CYP2C9 4842/4885 |
| US-20180235958-A1 | PANCREATITIS TREATMENT | IAPP, PNLIP, VIP | IL2 105/4885ALDH1A1 4027/4885CYP2C9 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.